DalCor Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2001 Boulevard Robert Bourassa Ste 1700,...Phone Number
(514) 508-5099Website
www.dalcorpharma.comRevenue
$5.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
3
1
1
1
1
About DalCor Pharmaceuticals
DalCor Pharmaceuticals is a biopharmaceutical company dedicated to addressing cardiovascular diseases through precision medicine. They are developing dalcetrapib, a pharmacogenetic treatment aimed at reducing the risk of recurrent myocardial infarction in patients with the AA genotype at the rs1967309 location in the ADCY9 gene. Currently, dalcetrapib is being evaluated in the Dal-GenE-2 Phase 3 clinical trial, following promising results from the earlier dal-GenE trial. The company targets patients with cardiovascular conditions, including those with obesity, diabetes, and hypertension.Explore more
DalCor Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is DalCor Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at DalCor Pharmaceuticals
Website visits: Recent activity has been detected on your website
Check out if DalCor Pharmaceuticals is spiking on competitors!
Product Launch: Get notified when DalCor Pharmaceuticals launches new products
Click to see if DalCor Pharmaceuticals had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if DalCor Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on DalCor Pharmaceuticals recently announced quarterly report
Funding: Get notified immidiatlly once DalCor Pharmaceuticals has new funding data
DalCor Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at DalCor Pharmaceuticals
Find 3 more new buyers
Compare Similar Companies to DalCor Pharmaceuticals
Compare insights from companies similar to DalCor Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
DalCor Pharmaceuticals
$5.4M
11-50
Private
$230M
-
DD
D. Michael DixonChief Financial Officer and Chef De La Direction Financière
Company Profile Activity
Activity Insights
DalCor Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
DalCor Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about DalCor Pharmaceuticals.
DalCor Pharmaceuticals financials insights
Gather financial insights about DalCor Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$50M
2016
Series B
$100M
2023
Series D
$80M
DalCor Pharmaceuticals Tech Stack
A closer look at the technologies used by DalCor Pharmaceuticals
See more technologies
DalCor Pharmaceuticals News & Media
DalCor Pharmaceuticals announces Dal-GenE-2 confirmatory - GlobeNewswire
MONTREAL, Sept. 13, 2023 (GLOBE NEWSWIRE) -- DalCor Pharmaceuticals today announced the closing of the company’s Series D financing round of $80m USD to...DalCor Announces Launch of Dalcetrapib Clinical Trial for COVID-19
New dal-COVID Phase 2 proof of concept study results anticipated in Q1 2021 New dal-COVID Phase 2 proof of concept study results anticipated in Q1 2021DalCor announces dal-GenE trial continues with final data expected in the first half of 2021
LONDON and MONTREAL, July 27, 2020 (GLOBE NEWSWIRE) -- DalCor Pharmaceuticals today announced that the independent dal-GenE Data and Safety Monitoring Board (DSMB) recommends the dal-GenE pivotal outcomes trial should continue as planned with no modifications. This is an important milestone for DalCor and for cardiovascular patients with the ADCY9 AA genotype.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding DalCor Pharmaceuticals
Sign Up For FreeTo access detailed company insights
DalCor Pharmaceuticals is a biopharmaceutical company dedicated to addressing cardiovascular diseases through precision medicine. They are developing dalcetrapib, a pharmacogenetic treatment aimed at reducing the risk of recurrent myocardial infarction in patients with the AA genotype at the rs1967309 location in the ADCY9 gene. Currently, dalcetra... Read More
